REG - Avacta Group PLC - Avacta to present at AACR-NCI-EORTC conference

AvactaAnnouncement

05/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231005:nRSE7387Oa&default-theme=true

RNS Number : 7387O  Avacta Group PLC  05 October 2023

 

 

 

 

 

5 October 2023

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

Avacta to present promising new data from Affimer® and pre|CISION(TM)
platform assets at AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics

 

·    AVA3996: FAP-α-activated proteasome inhibitor from pre|CISION(TM)
platform concentrates proteasome inhibitor payload in the tumour, increasing
the therapeutic index of this class of drugs

·    AVA032: anti-PD-L1 Affimer® fused to IL-15 demonstrates encouraging
in vitro and in vivo efficacy

 

Avacta Group plc (AIM: AVCT), a life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics, today
announces that it will be presenting two posters at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics, taking
place on 11-15 October 2023 in Boston Massachusetts.

 

Details of the poster presentations are as follows:

 

Abstract title:  AVA3996, a novel pre|CISION™ medicine, targets a warhead
to the tumor microenvironment via Fibroblast Activation Protein ("FAP")
mediated cleavage to elicit tumor cell kill

 

Poster number:
C169

Session:
               Poster Session
C

Session date and time:                  Saturday, October 14 |
12:30 pm-4:00 pm

Session location:
Level 2, Exhibit Hall D

 

Abstract title: A novel, tumor-targeted immunocytokine comprising an
anti-PD-L1 Affimer® fused to IL-15 exhibits potent anti-tumor activity

 

Poster number:
A077

Session:
               Poster Session
A

Session date and time:                  Thursday, October 12 |
12:30 pm-4:00 pm

Session location:
Level 2, Exhibit Hall D

 

Dr Fiona McLaughlin, Chief Scientific Officer of Avacta commented:

"We look forward to presenting the promising new data from Avacta's
Therapeutics platform assets at this conference. As disclosed in the Company's
announcement on 19 September 2023, our lead asset AVA6000 continues to advance
through the clinic at pace. We are simultaneously conducting IND-enabling
studies for promising assets derived from the pre|CISION(TM) and Affimer®
platforms. The data to be presented showcases the potential of our two
therapeutic platforms to generate further high value clinical assets.

 

"AVA3996, a FAP-α-activated proteasome inhibitor based on our pre|CISION(TM)
technology, demonstrates targeted killing of cancer cells in vitro and, by
concentrating the active warhead in the tumour, reduces systemic toxicity
associated with this class of drug.

 

"AVA032, our anti-PD-L1 Affimer® fused to the pro-inflammatory cytokine
interleukin 15 (IL-15) displays encouraging efficacy when tested in multiple
models of immunomodulation, stimulating a potent immune response and reversing
the immunosuppressive tumour microenvironment."

 

Further information regarding the conference can be found on the ACCR's
website here:
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/
(https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/)

 

The posters will be available to view following the conference here:
https://avacta.com/about/scientific-resources/
(https://avacta.com/about/scientific-resources/)

 

-Ends-

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                          Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                   www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Broker)                         Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / William   www.stifel.com (http://www.stifel.com/)
 Palmer-Brown

 Peel Hunt (Broker)                                                        Tel: +44 (0) 207 418 8900

 James Steel / Chris Golden / Patrick Birkholm                             www.peelhunt.com (http://www.peelhunt.com)

 ICR Consilium (Media and IR)                                              avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com/)

 

Avacta Group is a UK-based company focused on improving healthcare outcomes
through targeted cancer treatments and diagnostics.

 

Avacta has two divisions: an oncology biotech division harnessing proprietary
therapeutic platforms to develop novel, highly targeted cancer drugs, and a
diagnostics division, which is executing on an M&A led growth strategy to
create a full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta's two proprietary
platforms, Affimer® and pre|CISION™ underpin its cancer therapeutics whilst
the diagnostics division leverages the Affimer® platform to drive competitive
advantage in its markets.

 

The pre|CISION™ platform modifies chemotherapy to be activated only in the
tumour tissue, reducing systemic exposure and toxicity. This is achieved by
harnessing an enzyme called FAP which is highly upregulated in most solid
tumours compared with healthy tissues, turning chemotherapy into a "precision
medicine". The lead pre|CISION™ programme, AVA6000 a tumour activated form
of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in
safety compared with standard doxorubicin, and early signs of clinical
activity.

 

Affimer® is a novel biologic platform which has significant technical and
commercial advantages compared with antibodies and is used both to develop
advanced immunotherapies and to improve the performance of immunodiagnostics.

 

With a balanced business and capital allocation model: a high-value oncology
pipeline supported by a revenue generating, fast-growing diagnostics business,
Avacta seeks to create long-term shareholder value alongside patient benefit.

 

To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/)

 

About AVA3996

 

AVA3996 is a FAP-α-activated proteasome inhibitor, based on the Company's
pre|CISION(TM) technology platform. AVA3996 has the potential to become a
targeted cancer treatment for various indications, overcoming cytotoxicity
issues displayed when the free, non-targeted form of proteasome inhibitor is
systemically administered to patients.

 

About AVA032

 

AVA032 is an anti-PD-L1 Affimer® fused to the cytokine interleukin 15
("IL-15"). It carries improved properties compared to monoclonal antibodies,
currently used as cancer therapeutics, and works to reverse the
immunosuppressive tumour micro-environment, inducing a lasting immune response
aimed at stimulating a patient's immune system to destroy cancer cells.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSIFALEDSESS